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Interactions between bone and immune systems:  
A focus on the role of inflammation in bone resorption 
and fracture healing
Abstract
Functional interactions between the immune system and bone tissues are 
reflected in a number of cytokines, chemokines, hormones and other media-
tors regulating the functions of both bone and immune cells. Investigations 
of the mechanisms of those interactions have become important for the un-
derstanding of the pathogeneses of diseases like inflammatory arthritis, in-
flammatory bowel disease, periodontal disease and osteoporosis. This review 
first addresses the roles of the inflammatory mediators and mechanisms by 
which they cause inflammation-induced bone loss. In the second part of the 
review we stress the importance of proinflammatory mediators for normal 
fracture healing. Defective bone remodeling underlying different patho-
logical processes may be caused by disturbed differentiation and function of 
either osteoclast or osteoblast lineage cells. Understanding of the mechanisms 
governing enhanced differentiation and activation of osteoclast progenitors 
in the inflammatory conditions on the one hand, and the role of inflamma-
tion in the recruitment and differentiation of multipotent progenitors into 
the skeletal lineage during the fracture healing on the other hand is a criti-
cal first step in developing interventions that modulate bone regeneration 
processes and in designing novel pharmacological strategies.
INTRODUCTION
Bone growth and remodeling are essential processes, which create the marrow space for hematopoiesis, shape the bones during develop-
ment, adapt the bone tissue to changing biomechanical forces in the 
adult life, enable tooth eruption as well as regulate calcium and phos-
phorus homeostasis. On average, during normal bone remodeling in the 
adult human skeleton, 5–10% of the existing bone is replaced every year. 
Deregulated bone remodeling is a feature of a number of pathological 
states, including rheumatoid arthritis, hypercalcemia of malignancy, 
Paget’s disease and osteopetrosis. A large number of cytokines, chemo-
kines, hormones, tissue growth factors and other mediators are now 
known to influence bone cell functions and bone mass.
Bone cells
Bone tissue constantly undergoes remodeling by bone-resorbing os-
teoclasts and bone-forming osteoblasts in a tightly coordinated sequence 
of events referred to as coupling (1).
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Cells of the osteoblast lineage arise from the mesen-
chymal stem cells that have the ability to generate a diver-
sity of lineages including osteoblasts, adipocytes, chon-
drocytes, myocytes and cells that support hematopoiesis 
(2-6). During the process of osteoblastic differentiation, 
an osteoprogenitor proliferates and undergoes a series of 
maturational steps before becoming a differentiated os-
teoblast responsible for bone formation (7). Commitment 
of mesenchymal stem cells to the osteoblast lineage re-
quires the canonical Wnt/b-catenin pathway and associ-
ated proteins (8, 9).
Osteoclasts arise from hematopoietic progenitor cells 
of the monocyte/macrophage lineage that through a series 
of differentiation stages generate large multinucleated, 
tartrate-resistant acid phosphatase (TRAP)-positive cells 
capable of resorbing the mineralized matrix (10). Com-
mitted osteoclast progenitors express the receptor activator 
of nuclear factor kB (RANK) and can be matured in vitro 
into fully functional osteoclasts in the presence of macro-
phage colony-stimulating factor (M-CSF) and receptor 
activator of nuclear factor kB ligand (RANKL) (11).
Defective bone remodeling underlying different path-
ological processes may be caused by disturbed differen-
tiation and function of either osteoclast or osteoblast 
lineage cells. Cell culture techniques and mouse models 
with altered bone metabolism have advanced our under-
standing of molecular and cellular signals involved in the 
regulation of bone homeostasis.
Osteoimmunology
It has been almost 40 years since the first observations 
that cells of the immune system affect the functions of 
bone cells. Since then, we have greatly expanded our un-
derstanding of the interactions between hematopoietic, 
immune, and bone cells, which is now known as the field 
of „osteoimmunology” (12).
Immune cells and bone cells both originate from bone 
marrow environment and are closely functionally related. 
Crosstalk between the bone and the immune system is 
important for bone homeostasis and physiological bone 
remodeling. Members of the tumor necrosis factor 
(TNF)-related family of ligands and receptors (13,14), as 
well as other cytokines (15, 16), colony stimulating factors 
(17, 18), and signaling molecules (19, 20) are essential for 
normal development and function of both systems. This 
has been well documented in many experimental models 
and human diseases (13, 14, 17, 21). Moreover, it has been 
shown that bone and immune cells may share the same 
progenitors and that their differentiation may be driven 
by the same support cells (19). Multiple complex interac-
tions between hematopoietic and mesenchymal lineage 
cells define the bone marrow microenvironment (6,12).
Various immune mediators, particularly proinflamma-
tory cytokines and chemokines, may cause bone loss by 
stimulation of osteoclast formation and resorbing activity 
as well as by inhibition of osteoblast activity and bone 
formation. Production of cytokines by immune cells has 
been associated to human diseases such as rheumatoid 
arthritis and osteoporosis, causing an inflammation-in-
duced bone loss. On the other hand, some immune stim-
uli may support the osteoblast function and are important 
for the process of fracture healing and for the response of 
bone to infections.
In the first part of the review we will discuss the in-
flammatory mediators and mechanism by which they 
cause inflammation-induced bone loss, while in second 
we will stress the importance of proinflammatory media-
tors for normal fracture healing.
Inflammation-induced bone loss
Irreversible bone destruction, resulting from imbal-
anced remodeling processes, is a serious complication as-
sociated with localized bacterial infections of bones or 
adjacent tissues, being a key feature of caries, periodonti-
tis or osteomyelitis (22, 23). Bone loss is also observed in 
other inflammatory processes such as rheumatoid arthri-
tis, certain malignancies, osteoporosis, chronic viral infec-
tions and inflammatory bowel diseases (22-24). Mecha-
nisms underlying inflammation-induced bone loss have 
mainly been studied in various animal and in vitro mod-
els. Application of various Streptococcus strains or other 
Gram-positive bacteria, which are the most often cause of 
osteomyelitis and posttraumatic infections, is a typical 
model used in studies of these diseases (25). On the other 
hand, periodontitis and the inflammatory milieu that 
causes a systemic bone loss, which will be the main topic 
of our review, are most often induced by application of 
lipopolysaccharide (LPS), a major component of the cell 
wall of Gram-negative bacteria that increases the produc-
tion of bone-resorptive factors and creates microenviron-
ments that promote the differentiation of monocytes into 
bone-resorbing osteoclasts causing enhanced bone resorp-
tion (26).
LPS exerts its effects through the activation of Toll like 
receptor 4 (TLR4), which is expressed on both principal 
bone cell lineages: osteoblasts and osteoclasts (27-29). 
Studies in vitro suggest that LPS supports the survival of 
osteoclasts directly and, at least in part, independently of 
the production of pro-osteoclastogenic cytokines, such as 
interleukin (IL)-1b, TNF-a, and RANKL (28,30). How-
ever, Liu et al. demonstrated that LPS plays a bifunc-
tional role in osteoclastogenesis by inhibiting osteoclast 
formation from naïve osteoclast precursors, but promot-
ing osteoclastogenesis from precursors primed with 
RANKL (31). Studies on culture models supportive for 
osteoblast differentiation have shown that activation of 
TLR4 on osteoblast lineage cells induces gene expression 
for RANKL in differentiating osteoblasts (32) and, at the 
same time, has an inhibitory effect on late osteoblast dif-
ferentiation (27, 33). In in vivo conditions, LPS has an 
additional indirect effect in promoting bone destruction, 
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by activation of macrophages and other immune cells that 
contribute to the inflammatory environment.
In animals LPS can be applied either topically to cause 
local bone loss (in the gingival tissue as a model of peri-
odontitis or in calvaria) or to cause systemic bone loss (by 
intraperitoneal injection). The significant bone loss occurs 
7-20 days after the onset of inflammation and is charac-
terized by enhanced osteoclast and suppressed osteoblast 
activity. Our preliminary results confirmed increased fre-
quency and activity of circulating osteoclast progenitor 
cells after LPS treatment (unpublished data). These effects 
are associated with an increased production of osteore-
sorptive cytokines including IL-1, IL-6, IL-11, IL-17, 
TNF-a, RANKL, as well as several chemokines impor-
tant for trafficking of cells mediating bone homeostasis 
(33-39). However, the specific mechanisms of the effects 
of inflammatory and immune cells on osteoclast lineage 
cell migration, homing and differentiation are not fully 
elucidated and are still the subject of the ongoing investi-
gations.
In vivo effect of LPS administration is mainly medi-
ated by induced production of various proinflammatory 
cytokines such as TNF-a, IL-1, IL-3, IL-6, IL-8, IL-12, 
IL-17 (40, 41), many of which have the potential to acti-
vate bone resorption and promote bone loss. Moreover, 
RANKL, expressed on osteoblasts and hypertrophying 
chondrocytes, as well as on activated T lymphocytes, may 
be up-regulated by pro-resorptive cytokines and media-
tors, such as prostaglandin E2, IL-1, IL-7, IL-11, IL-17 and 
IL-23 (42-44). Administration of TNF-a in vivo stimu-
lates osteoclast formation and bone resorption (45, 46), 
possibly by increasing the number of circulating osteo-
clast precursors and by promoting their proliferation and 
differentiation in bone marrow through the up-regulation 
of c-Fms expression (receptor for M-CSF) (47). TNF-a 
can act in a RANKL-dependent and -independent man-
ner, directly on osteoclast progenitors that express TNF-
receptors (48-50). Inhibitory effects of TNF-a on osteo-
blast differentiation, through the suppression of RUNX2 
and osterix, have also been reported (51, 52). Furthermore 
TNF-a stimulates the production of IL-1, which is a po-
tent inducer of osteoclastogenesis and bone resorption by 
a RANKL-dependent mechanism (53, 54). Although it 
is generally accepted that IL-1 induces bone loss by stim-
ulating the formation, survival and function of osteo-
clasts, its inhibitory effects on osteoblasts may contribute 
to decreased bone mineral density (55). Levels of IL-6 are 
also highly increased after the LPS treatment, but the 
reports on its influence on bone cells are inconsistent, as 
both stimulatory and inhibitory effects have been ob-
served (56, 57, 58). Proinflammatory cytokines IL-12 and 
IL-18, up-regulated by LPS, are not likely to mediate 
inflammation-induced bone loss, as a majority of pub-
lished reports suggest their inhibitory effect on osteoclast 
differentiation (59, 60, 61). On the other hand IL-17 
stimulates osteoclast differentiation (62, 63) and induces 
RANK expression on osteoclast progenitors (64). Zweri-
na et al. have reported that anti IL-17A therapy inhibits 
bone loss in TNF-a-mediated murine arthritis (65).
Products of arachidonic acid metabolism are also crit-
ically involved in LPS-induced bone loss. LPS treatment 
induces the production of PGE2 in osteoblasts (66), which 
acts as a potent stimulator of bone resorption (67, 68). 
Hikiji et al. demonstrated that mice deficient in the high-
affinity leukotriene B4 (LTB4) receptor BLT1 are protect-
ed from LPS-induced bone resorption (69). In line with 
this study Lee et al. have recently reported that inhibition 
of 5-lipoxygenase, an enzyme that catalyzes the formation 
of LTB4 and cysteinyl leukotrienes, suppressed the LPS-
induced osteoclast formation and bone loss (70).
Pro-inflammatory mediators  
in the fracture healing process
Bone fractures are common injuries that generally heal 
by forming new bone in a rapid and efficient process. The 
fracture healing cascade involves the formation of a blood 
clot at the site of injury, an inflammatory phase, callus 
generation, primary bone induction, and secondary bone 
remodeling. However, in about 5-10% of patients fracture 
healing fails, and a delayed union or nonunion develops, 
associated with a significant cost and largely ineffective 
current therapies (71,72). Nonunion and segmental bone 
loss after fractures often require multiple surgical proce-
dures associated with patient morbidity and reduced qual-
ity of life.
Bone formation during fracture healing is a complex 
process that involves multiple cell lineages and is still not 
fully understood. During bone regeneration, mesenchy-
mal cells proliferate and differentiate along a cartilaginous 
or osteoblastic lineage in response to growth factors and 
cytokines (73,74). Regeneration of adult skeletal tissues 
requires a timely recruitment of skeletal progenitor cells 
to an injury site, differentiation of these cells into bone or 
cartilage, and re-establishment of a vascular network to 
maintain cell viability (71,72,75,76).
In contrast to fetal skeletal development, reparative 
skeletal healing involves an initial hematoma formation 
and an inflammatory response (77). Minimizing hema-
toma formation by removing bone marrow delays the 
periosteal response (78). In addition, macrophages appear 
to modulate bone formation during bone healing, where-
as osteoclasts are required for the remodeling phase (79). 
Thus, it has been postulated that inflammation is an 
early physiological response to fracture injury and criti-
cally contributes to initiation of the tissue regeneration 
pathway. In line with this hypothesis it was shown that 
treatment with anti-inflammatory drugs such as non ste-
roid anti-inflammatory drugs or corticosteroids impairs 
fracture healing (80-83). Moreover, the inhibition of os-
teal macrophages delays fracture healing, whereas the 
administration of M-CSF, a macrophage growth factor, 
had an opposite effect (79).
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Up-regulation of TNF-a, IL-1, IL-6, IL-17 and IL-18 
occurs in fracture calluses soon after injury (84-86). The 
post-fracture expression pattern of TNF-a and IL-1 has 
two peaks: the first peak occurs within the first 24 hours 
and a second peak after 3-4 weeks (87). Glass et al. have 
shown that local injections of TNF-a promote fracture 
healing in the mouse tibial fracture model by augmenting 
the recruitment and differentiation of muscle-derived 
stromal cells (88). Similarly, it was reported that mice 
deficient for TNF-a receptors (p55(-/-)/p75(-/-)) have im-
paired fracture healing (89). However, in a recent study 
Sandberg et al. found that blocking of TNF-a with etan-
ercept had no substantial influence on the fracture healing 
process (90). This discrepancy might be explained by 
model differences and also by an incomplete inhibition of 
TNF-a receptors activation achieved by etanercept. Al-
though etanercept inhibits both biological ligands for 
TNF-a receptors, i.e. TNF-a and lymphotoxin-a (91), 
the biological effectiveness of applied dose, as discussed 
by Sandberg et al, was uncertain (90).
In the model of fracture repair IL-b stimulated the 
proliferation of osteoblasts and the production of miner-
alized bone matrix, but suppressed the proliferation and 
inhibited the differentiation of bone marrow derived mes-
enchymal stem cells. The functional testing in vivo 
showed that its overall effect on fracture healing was 
minimal, including only slightly accelerated cartilage and 
bone formation (92). The studies on mice deficient for the 
IL-6 gene showed that these mice have an impaired early 
phase of the fracture healing process. However, no differ-
ence in histological and biomechanical parameters be-
tween the wild type and IL-6 knockout mice was found 
at the later time points of fracture healing (93, 94). In our 
preliminary studies we observed that inflammatory me-
diators induced by proinflammatory cytokines, such as 
pentraxin 3, may be important for bone healing (unpub-
lished data). Less obvious is the importance of adaptive 
immune response in the bone regeneration processes. To-
ben et al. reported that mice deficient for the recombina-
tion activating gene 1 (RAG1), lacking the adaptive im-
mune system, have an accelerated endochondral 
ossification after the closed femoral fracture (95). On the 
other hand, Nam et al. found an impaired tibial fracture 
healing and suggested RAG1 knockout mouse model as 
a suitable for studying impaired fracture healing (86).
Figure 1. Schematic presentation of the role of pro-inflammatory mediators in inflammation induced bone loss and in fracture healing. On the 
left side inflammation induced-bone loss is shown. Overproduction of IL-1, TNF-a and PGE2 stimulates osteoclastogenesis through direct 
activation of osteoclast precursors and indirecly, by inducing RANKL expression in osteoblasts. Osteoclastogenesis is negatively controlled by 
IL-12 and IL-18. At the same time, proinflammatory mediators negatively regulate osteoblast differentiation and bone formation. On the right 
side, fracture healing process is shown. In the inflammatory phase, up-regulation of IL-6, TNF-a and PGE2 stimulates the proliferation of 
mesenchymal stem cells and promotes their differentiation to mature osteoblasts. Treatment with NSAID in this phase suppresses PGE2 produc-
tion and subsequently delay the fracture healing. IL-1 stimulates the proliferation of osteoblasts and the production of mineralized bone matrix, 
but suppresses the proliferation and differentiation of mesenchymal stem cells. Osteoblast differentiation is negatively regulated by 5-lipoxygen-
ase products. In the remodeling phase of fracture healinf, IL-1 and TNF-a are important for osteoclast activation. For simplicity only selected 
regulators and interactions are shown. OCL - osteoclast, OCP – osteoclast progenitor, OBL – osteoblast, MSC – mesenchymal stem cell 5-LO 
– 5-lipoxygenase.
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Further proofs for the involvement of the immune sys-
tem in bone healing are investigations on the products of 
arachidonic acid metabolism, which influence bone regen-
eration as well as bone resorption. Treatments with cyclo-
oxigenase inhibitors, such as indomethacin and celecoxib 
prolong the fracture healing process (82, 83). A positive 
effect of cycloxigenase activation on fracture healing ap-
pears to be mediated by PGE2. Studies on animal models 
showed that administration of PGE2, or its agonists, stim-
ulates bone induction and callus fomation (96, 97). Studies 
investigating PGE2 agonists selective for EP2 or EP4 recep-
tors showed that they accelerate fracture healing (97, 98). 
Thus, we can propose that PGE2 exerts its bone regenerative 
properties through the activation of these two receptors. 
Accordingly, Li et al. observed an impaired fracture healing 
in EP4 knockout mice (99). On the other hand, signaling 
through the activation of EP1 receptor negatively regulates 
the fracture healing process (100). In contrast to the cy-
cloxigenase activation, activation of 5-lipoxygenase appears 
to suppress fracture healing. Manigrasso et al reported on 
accelerated fracture healing in mice lacking the 5-lipoxy-
genase gene (101). Cottrell et al. recently found that a local 
inhibition of 5-lipoxygenase enhances bone formation in a 
unicortical femoral defect model in rats (102).
CONCLUSION
The crosstalk between the bone and the immune sys-
tems is important for bone homeostasis and physiological 
bone remodeling. Sustained inflammation can stimulate 
osteoclast activity and their differentiation from osteoclast 
precursors, causing, eventually, a decreased bone mineral 
density. Inflammatory cytokines, particularly TNF-a, 
IL-1 and IL-17 play a key role in the pathogenesis of the 
inflammation-induced bone loss. Their effect is, at least 
partially, mediated through the stimulation of cycloxygen-
ase, mainly because of an increase in PGE2 production. On 
the other hand, the inflammation is critically important 
for the early phase of normal fracture healing. Inflamma-
tory mediators, particularly TNF-a, IL-6 and PGE2, are 
induced immediately after the fracture injury. They stimu-
late proliferation of mesenchymal stem cells and promote 
their differentiation to mature osteoblasts. The role of the 
most important pro-inflammatory mediators in inflam-
mation-induced bone loss and in fracture healing is sum-
marized schematically in Figure 1. Understanding of the 
mechanisms governing enhanced differentiation and acti-
vation of osteoclast progenitors in the inflammatory condi-
tions on the one hand, and the role of inflammation in the 
recruitment and differentiation of multipotent progenitors 
into the skeletal lineage during the fracture healing on the 
other hand is a critical first step in developing interventions 
that modulate bone regeneration processes and in design-
ing novel pharmacological strategies.
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